Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 5/20 | 0.47 |
| ▸ | CES1 | P23141 | 4/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748949 | 0.88 | CES1 (0.47) | ALDH1A1TGM2CES1MAOAMAOB | |
| SCHEMBL1050601 | 0.75 | SMYD3 (0.56) | ALDH1A1TGM2CES1SMYD3MAOA | |
| SCHEMBL29631093 | 0.75 | SMYD3 (0.56) | ALDH1A1TGM2CES1SMYD3MAOA | |
| SCHEMBL14563297 | 0.73 | TGM2 (0.58) | ALDH1A1TGM2CES1SMYD3MAOA | |
| SCHEMBL30706261 | 0.73 | SMYD3 (0.55) | ALDH1A1TGM2CES1SMYD3MAOA | |
| SCHEMBL5893915 | 0.73 | SMYD3 (0.55) | ALDH1A1TGM2CES1SMYD3MAOA | |
| SCHEMBL25682260 | 0.73 | TTR (0.58) | ALDH1A1MAOACASP3 | |
| SCHEMBL5894291 | 0.73 | ALDH1A1 (0.49) | ALDH1A1TGM2CES1SMYD3MAOA | |
| SCHEMBL22380701 | 0.73 | PDPK1 (0.57) | ALDH1A1TGM2CES1SMYD3CA12 | |
| SCHEMBL5894294 | 0.73 | ALDH1A1 (0.49) | ALDH1A1TGM2CES1SMYD3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | ALDH1A1 324/4885TGM2 4068/4885CES1 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.